Eli Lilly & CO Form 4 insider transactions

Director Juan R. Luciano acquired 17.304 shares of Eli Lilly & Co common stock on February 18, 2025, under the company's Directors' Deferral Plan.

Director Mary Lynne Hedley acquired 11.569 shares of Eli Lilly & Co (LLY) common stock at $857.2 per share through the Lilly Directors' Deferral Plan.

Director J Erik Fyrwald acquired 11.569 shares of Eli Lilly & Co common stock at $857.2 per share on February 18, 2025, under the Lilly Directors' Deferral Plan.

Director Ralph Alvarez acquired 13.708 shares of Eli Lilly common stock through the Lilly Directors' Deferral Plan, deferring cash compensation into stock units.

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co, reports selling shares in multiple transactions on February 13, 2025.

EVP & President of Eli Lilly International, Ilya Yuffa, reports acquisition and disposal of common stock and acquisition of restricted stock units.

EVP & President of Lilly Neuroscience, Anne E. White, reports acquiring common stock and restricted stock units of Eli Lilly & Co.

EVP & President of Lilly Oncology, Jacob Van Naarden, reports acquisition and disposal of Eli Lilly & Co. common stock and restricted stock units.

Diogo Rau, EVP & CIDO of Eli Lilly & Co, reports acquisition and disposal of common stock and acquisition of restricted stock units.

Lucas Montarce, EVP & CFO of Eli Lilly & Co, reports acquiring 2,895.932 shares of common stock at $868.88 per share on February 10, 2025.

EVP & President of Eli Lilly, Patrik Jonsson, reports acquisition of common stock and restricted stock units.

EVP & Pres., Mfg. Operations Edgardo Hernandez reports acquisition of common stock and restricted stock units, along with a disposition of common stock.

Donald A. Zakrowski, SVP, Finance, & CAO of Eli Lilly & Co, reports acquisition of common stock and restricted stock units.

Eric Dozier, EVP, HR & Diversity at Eli Lilly & Co, reports acquiring common stock and restricted stock units.

David Ricks, CEO of Eli Lilly, reports acquisition of common stock and restricted stock units.

Anat Hakim, EVP, GC & Secretary of Eli Lilly & Co, reports acquiring shares and restricted stock units, increasing her direct and indirect beneficial ownership.

Daniel Skovronsky, EVP, CSO & President of LRL & LLY Imm at Eli Lilly & Co, reported the sale of common stock and acquisition of restricted stock units on February 10, 2025, according to a Form 4 filing.

Lilly Endowment Inc., a major shareholder of Eli Lilly & Co., reports selling 96,119 shares of LLY common stock on February 6, 2025, at prices ranging from $866.067 to $887.316.

EVP & President of Eli Lilly International, Ilya Yuffa, reports the acquisition and disposal of company stock on February 1, 2025.

EVP and President of Lilly Neuroscience, Anne E. White, reports the vesting of restricted stock units and subsequent disposition of shares to cover tax obligations.

EVP & President of Lilly Oncology, Jacob Van Naarden, reports the acquisition and disposal of Eli Lilly & Co. common stock and restricted stock units on February 1, 2025.

An Eli Lilly executive exercised stock options and sold a portion of the acquired shares, according to a recent SEC filing.

David Ricks, CEO of Eli Lilly, reports the acquisition and disposal of company stock and derivative securities on February 1, 2025.

Diogo Rau, EVP & CIDO of Eli Lilly & Co, reports the acquisition and disposal of common stock and restricted stock units on February 1, 2025.

Patrik Jonsson, an EVP at Eli Lilly, reported transactions involving common stock and restricted stock units on February 1, 2025.

EVP Edgardo Hernandez reports the acquisition and disposal of Eli Lilly common stock and restricted stock units on February 1, 2025.

Anat Hakim, EVP, GC & Secretary of Eli Lilly & Co, reports the acquisition and disposal of common stock and restricted stock units on February 1, 2025.

Director Gabrielle Sulzberger reports acquiring 6.679 shares of Eli Lilly & Co common stock at $742.35 per share through the Lilly Directors' Deferral Plan.

Director Juan R. Luciano acquired shares of Eli Lilly & Co. under the company's Directors' Deferral Plan, deferring cash compensation into stock units.

Mary Lynne Hedley, a director at Eli Lilly & Co, acquired shares of common stock under the Lilly Directors' Deferral Plan.